Nomura Asset Management Co. Ltd. Sells 2,584 Shares of Hologic, Inc. (NASDAQ:HOLX)

Nomura Asset Management Co. Ltd. reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,801 shares of the medical equipment provider’s stock after selling 2,584 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Hologic were worth $2,343,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC grew its stake in Hologic by 3,466.7% in the second quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 520 shares during the period. SevenBridge Financial Group LLC grew its stake in Hologic by 172.0% in the second quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock worth $58,000 after purchasing an additional 762 shares during the period. Advisory Services Network LLC grew its stake in Hologic by 12.2% in the second quarter. Advisory Services Network LLC now owns 2,028 shares of the medical equipment provider’s stock worth $97,000 after purchasing an additional 220 shares during the period. Rockefeller Capital Management L.P. grew its stake in Hologic by 127.6% in the first quarter. Rockefeller Capital Management L.P. now owns 2,162 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 1,212 shares during the period. Finally, Pearl River Capital LLC purchased a new stake in Hologic in the second quarter worth $126,000. 95.15% of the stock is currently owned by hedge funds and other institutional investors.

HOLX has been the topic of several recent research reports. Piper Jaffray Companies upped their price target on Hologic from $49.00 to $59.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research note on Friday, August 16th. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a report on Saturday, July 27th. Argus boosted their target price on Hologic to $62.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, TheStreet raised Hologic from a “c+” rating to a “b” rating in a report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $50.12.

Hologic stock traded up $0.15 during mid-day trading on Thursday, hitting $50.14. The company had a trading volume of 98,277 shares, compared to its average volume of 1,339,854. The company has a current ratio of 1.57, a quick ratio of 1.11 and a debt-to-equity ratio of 1.27. The stock’s 50 day moving average price is $49.63 and its two-hundred day moving average price is $47.52. Hologic, Inc. has a 12 month low of $37.47 and a 12 month high of $52.19. The company has a market capitalization of $13.22 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 2.25 and a beta of 0.78.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.02. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The business had revenue of $852.40 million for the quarter, compared to the consensus estimate of $836.91 million. During the same period in the previous year, the company posted $0.58 earnings per share. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. Equities research analysts anticipate that Hologic, Inc. will post 2.44 EPS for the current year.

In other news, Chairman Stephen P. Macmillan sold 194,396 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $48.77, for a total transaction of $9,480,692.92. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Peter J. Valenti III sold 7,766 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total value of $381,621.24. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: What is the return on assets (ROA) ratio?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit